Journal article

Amyloid-beta, Tau, and F-18-Fluorodeoxyglucose Positron Emission Tomography in Posttraumatic Stress Disorder

Alby Elias, Tia Cummins, Fiona Lamb, Regan Tyrrell, Vincent Dore, Rob Williams, Jeffrey Rosenfeld, Malcolm Hopwood, Victor L Villemagne, Christopher C Rowe

Journal of Alzheimer's Disease | IOS PRESS | Published : 2020

Abstract

BACKGROUND: Epidemiological studies suggest a relationship between posttraumatic stress disorder (PTSD) and dementia. OBJECTIVE: This study assessed whether Alzheimer's disease (AD) imaging biomarkers were elevated in Vietnam veterans with PTSD. METHODS: The study compared cognition, amyloid-β, tau, regional brain metabolism and volumes, and the effect of APOE in 83 veterans with and without PTSD defined by the Clinician-Administered PTSD Scale. RESULTS: The PTSD group had significantly lower education, predicted premorbid IQ, total intracranial volume, and Montreal Cognitive Assessment score compared with the controls. There was no difference between the two groups in the imaging or genetic..

View full abstract

Grants

Funding Acknowledgements

The authors thank the U.S. Department of Defense and Piramal Pharmaceuticals for supporting this study. The study utilized the infrastructure and resources of Australian Imaging Biomarkers and Lifestyle (AIBL) Study of ageing.ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujire-bio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org).The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNIdata are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.